Short Interest in Chimerix, Inc. (NASDAQ:CMRX) Decreases By 27.9%

Chimerix, Inc. (NASDAQ:CMRX - Get Free Report) was the target of a large decrease in short interest in the month of March. As of March 15th, there was short interest totalling 3,410,000 shares, a decrease of 27.9% from the February 28th total of 4,730,000 shares. Approximately 4.3% of the company's shares are short sold. Based on an average daily trading volume, of 3,850,000 shares, the short-interest ratio is currently 0.9 days.

Chimerix Trading Up 0.1 %

CMRX traded up $0.01 during trading hours on Thursday, hitting $8.53. 1,010,459 shares of the company's stock were exchanged, compared to its average volume of 2,134,918. The firm has a 50 day moving average of $6.13 and a 200 day moving average of $3.27. The firm has a market cap of $800.15 million, a P/E ratio of -9.07 and a beta of -0.18. Chimerix has a 12-month low of $0.75 and a 12-month high of $8.53.

Chimerix (NASDAQ:CMRX - Get Free Report) last released its earnings results on Friday, March 21st. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.26) by $0.01. The company had revenue of $0.06 million during the quarter, compared to analysts' expectations of $0.31 million. As a group, research analysts expect that Chimerix will post -0.99 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently issued reports on CMRX. StockNews.com began coverage on shares of Chimerix in a research note on Monday. They issued a "hold" rating on the stock. Wedbush restated a "neutral" rating and set a $8.55 price target (up from $7.00) on shares of Chimerix in a research note on Wednesday, March 5th. HC Wainwright restated a "neutral" rating and set a $8.55 price target (down from $11.00) on shares of Chimerix in a research report on Wednesday, March 5th. Finally, Jefferies Financial Group reiterated a "hold" rating and issued a $8.50 price objective (down previously from $10.00) on shares of Chimerix in a report on Wednesday, March 5th.

Insider Activity

In related news, CEO Michael T. Andriole sold 7,370 shares of the firm's stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $4.52, for a total transaction of $33,312.40. Following the completion of the sale, the chief executive officer now directly owns 609,603 shares of the company's stock, valued at approximately $2,755,405.56. This trade represents a 1.19 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 20,760 shares of company stock valued at $91,175 in the last 90 days. Company insiders own 13.10% of the company's stock.

Institutional Trading of Chimerix

Several hedge funds have recently added to or reduced their stakes in CMRX. Assenagon Asset Management S.A. increased its position in shares of Chimerix by 154.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company's stock valued at $2,846,000 after purchasing an additional 496,823 shares during the last quarter. Charles Schwab Investment Management Inc. acquired a new position in shares of Chimerix during the 4th quarter worth about $183,000. Rosalind Advisors Inc. purchased a new position in shares of Chimerix in the 4th quarter valued at about $10,614,000. Palumbo Wealth Management LLC purchased a new stake in Chimerix during the fourth quarter worth approximately $221,000. Finally, Valeo Financial Advisors LLC increased its stake in Chimerix by 78.8% in the fourth quarter. Valeo Financial Advisors LLC now owns 146,186 shares of the biopharmaceutical company's stock valued at $509,000 after purchasing an additional 64,420 shares during the last quarter. Institutional investors and hedge funds own 45.42% of the company's stock.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.